Dyadic International Inc (DYAI)vsRoyalty Pharma Plc (RPRX)
DYAI
Dyadic International Inc
$0.71
-1.77%
HEALTHCARE · Cap: $25.89M
RPRX
Royalty Pharma Plc
$55.02
-1.09%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 63994% more annual revenue ($2.44B vs $3.81M). RPRX leads profitability with a 33.9% profit margin vs -191.5%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
DYAI
Avoid23
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+83.2%
Fair Value
$4.73
Current Price
$0.71
$4.02 discount
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 182.3% year-over-year
Conservative balance sheet, low leverage
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -2827.0% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DYAI
The strongest argument for DYAI centers on Revenue Growth, Debt/Equity. Revenue growth of 182.3% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : DYAI
The primary concerns for DYAI are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
DYAI profiles as a hypergrowth stock while RPRX is a mature play — different risk/reward profiles.
DYAI carries more volatility with a beta of 1.17 — expect wider price swings.
DYAI is growing revenue faster at 182.3% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 23/100), backed by strong 33.9% margins and 11.0% revenue growth. DYAI offers better value entry with a 83.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dyadic International Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Dyadic International, Inc., a biotechnology platform company, develops, produces and sells enzymes and other proteins in the United States. The company is headquartered in Jupiter, Florida.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?